Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase Ia Clinical Trial of HW241045
Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Summary
This is a Phase Ia, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetic (PK) of HW241045 in healthy subjects following a single ascending dose.
Official title: A Phase Ia Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of HW241045 Tablets Following a Single Dose in Healthy Subjects: A Single-center, Randomized, Double-blind, Placebo-controlled Study
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2025-11-24
Completion Date
2026-06
Last Updated
2026-03-04
Healthy Volunteers
Yes
Conditions
Interventions
HW241045
Dose 1 to Dose 7
Placebo
Dose 1 to Dose 7
Locations (1)
Peking Union Medical College Hospital
Beijing, China